FATE THERAPEUTICS INC (FATE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 32.59M USD | Liabilities, Current |
| Cash and equivalents | 32.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 703.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $32.59M | $32.43M | (m) | $703.00K | (m) | (m) |
| 2026-03-31 | (m) | $30.69M | $39.57M | (m) | $704.00K | (m) | (m) |
| 2025-12-31 | (m) | $36.07M | $46.63M | (m) | $916.00K | (m) | (m) |
| 2025-09-30 | (m) | $28.11M | $40.62M | (m) | $682.00K | (m) | (m) |
| 2025-06-30 | (m) | $28.67M | $41.25M | (m) | $1.40M | (m) | (m) |
| 2025-03-31 | (m) | $28.16M | $44.92M | (m) | $2.41M | (m) | (m) |
| 2024-12-31 | (m) | $38.52M | $36.06M | (m) | $3.54M | (m) | (m) |
| 2024-09-30 | (m) | $37.42M | $37.91M | (m) | $4.13M | (m) | (m) |
| 2024-06-30 | (m) | $34.79M | $36.92M | (m) | $1.05M | (m) | (m) |
| 2024-03-31 | (m) | $45.37M | $121.32M | (m) | $858.00K | (m) | (m) |
| 2023-12-31 | (m) | $39.09M | $41.87M | (m) | $1.83M | (m) | (m) |
| 2023-09-30 | (m) | $41.33M | $33.33M | (m) | $1.54M | (m) | (m) |
| 2023-06-30 | (m) | $44.69M | $46.80M | (m) | $2.83M | (m) | (m) |
| 2023-03-31 | (m) | $48.65M | $42.02M | (m) | $13.50M | (m) | (m) |
| 2022-12-31 | (m) | $114.05M | $61.33M | (m) | $38.48M | (m) | (m) |
| 2022-09-30 | (m) | $103.94M | $82.09M | (m) | $10.22M | (m) | (m) |
| 2022-06-30 | (m) | $91.52M | $55.27M | (m) | $13.13M | (m) | (m) |
| 2022-03-31 | (m) | $77.91M | $64.74M | (m) | $13.85M | (m) | (m) |
| 2021-12-31 | (m) | $81.28M | $133.58M | (m) | $8.68M | (m) | (m) |
| 2021-09-30 | (m) | $91.88M | $129.18M | (m) | $7.31M | (m) | (m) |
| 2021-06-30 | (m) | $105.60M | $76.65M | (m) | $10.30M | (m) | (m) |
| 2021-03-31 | (m) | $94.58M | $106.41M | (m) | $6.95M | (m) | (m) |
| 2020-12-31 | (m) | $85.56M | $167.35M | (m) | $5.51M | (m) | (m) |
| 2020-09-30 | (m) | $54.20M | $349.13M | (m) | $3.24M | (m) | (m) |
| 2020-06-30 | (m) | $45.32M | $433.07M | (m) | $1.72M | (m) | (m) |
| 2020-03-31 | (m) | $24.92M | $83.37M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $27.81M | $99.81M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $40.59M | $249.59M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $29.42M | $71.44M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $29.14M | $183.03M | (m) | $500.00K | (m) | (m) |
| 2018-12-31 | (m) | $27.26M | $190.51M | (m) | $500.00K | (m) | (m) |
| 2018-09-30 | (m) | $22.67M | $183.25M | (m) | $500.00K | (m) | (m) |
| 2018-06-30 | (m) | $16.27M | $36.16M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $12.59M | $32.91M | (m) | $500.00K | (m) | (m) |
| 2017-12-31 | (m) | $11.05M | $88.95M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $9.72M | $43.23M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $8.05M | $31.06M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $16.90M | $40.61M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $15.19M | $88.61M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $14.68M | $37.10M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $14.33M | $35.87M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $13.89M | $39.49M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $13.44M | $64.81M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $12.60M | $72.86M | (m) | $846.00K | (m) | (m) |
| 2015-06-30 | (m) | $11.31M | $81.18M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $6.41M | $42.35M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $4.58M | $49.10M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.91M | $45.53M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $3.81M | $42.01M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $4.35M | $47.88M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $4.60M | $54.04M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $9.49M | $19.08M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $3.40M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $4.65M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $4.85M | $9.09M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $5.46M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $6.39M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $11.22M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |